Temporal trends revealed that discussions of adverse events increased significantly after notable events, including government approvals, viral media coverage, celebrity endorsements, and the expansion of Medicare coverage for weight loss medications
Diabetes Care 44 , 13851392 (2021)
Government hospitals: Where GLP-1s are available via tenders, they may be dispensed free or at heavily subsidised rates to selected high-risk patients, though this is still limited and uneven across states.[9] 4.3 Government Schemes and Insurance Ayushman Bharat (AB-PMJAY): As per recent parliamentary responses, there is currently no wide-scale inclusion of GLP-1 receptor agonists under AB-PMJAY packages.[5] State schemes: A few better-resourced state programmes and teaching institutions may provide GLP-1s to high-risk diabetes patients through special budgets or pilot projects, but this is not yet mainstream.[9] Private insurance: Most retail health insurance still focuses on hospitalisation, not long-term outpatient medicines
By combining the beneficial effects of GLP-1 and GIP signaling with glucagon-mediated thermogenesis, retatrutide delivers robust improvements in body weight regulation, glycemic control, and overall metabolic health